Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
pubmed:
3
1
2020
medline:
15
12
2020
entrez:
3
1
2020
Statut:
ppublish
Résumé
The aim of the current study was to determine patient-reported functional outcomes in men with prostate cancer (PCa) undergoing moderately hypofractionated (H-RT) or conventionally fractionated radiation therapy (C-RT) in a national cohort study. All men diagnosed with PCa between April 2014 and September 2016 in the English National Health Service undergoing C-RT or H-RT were identified in the National Prostate Cancer Audit and mailed a questionnaire at least 18 months after diagnosis. We estimated differences in patient-reported urinary, bowel, sexual, and hormonal function-Expanded Prostate Cancer Index Composite short-form 26 domain scores on a 0 to 100 scale-and health-related quality of life-EQ-5D-5L on a 0 to 1 scale-using linear regression with adjustment for patient, tumor, and treatment-related factors in addition to GI and genitourinary baseline function, with higher scores representing better outcomes. Of the 17,058 men in the cohort, 77% responded: 8,432 men received C-RT (64.2%) and 4,699 H-RT (35.8%). Men in the H-RT group were older (age ≥ 70 years: 67.5% This is the first national cohort study comparing functional outcomes after H-RT and C-RT reported by patients. These real-world results further support the use of H-RT as the standard for radiation therapy in men with nonmetastatic PCa.
Identifiants
pubmed: 31895608
doi: 10.1200/JCO.19.01538
pmc: PMC7048158
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
744-752Subventions
Organisme : Department of Health
ID : DRF-2018-11-ST2-036
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S020470/1
Pays : United Kingdom
Références
Br J Cancer. 2018 Feb 20;118(4):489-494
pubmed: 29348490
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1253-1260
pubmed: 28974414
ACR Open Rheumatol. 2019 Aug 19;1(8):493-498
pubmed: 31777830
Br J Surg. 2010 May;97(5):772-81
pubmed: 20306528
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Urol. 1998 Jun;159(6):1988-92
pubmed: 9598504
J Urol. 2013 Jan;189(1 Suppl):S59-65; discussion S65
pubmed: 23234635
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Lancet Oncol. 2016 Apr;17(4):464-474
pubmed: 26968359
JAMA Oncol. 2019 May 1;5(5):664-670
pubmed: 30763425
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Eur Urol Focus. 2019 Jul;5(4):577-584
pubmed: 29221876
Lancet Oncol. 2015 Dec;16(16):1605-16
pubmed: 26522334
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):555-67
pubmed: 26068490
Urology. 2010 Nov;76(5):1245-50
pubmed: 20350762
Lancet Oncol. 2019 Feb;20(2):e112-e123
pubmed: 30712798
J Public Health (Oxf). 2012 Mar;34(1):108-14
pubmed: 21745831
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-731
pubmed: 28244407
Cancer J. 2009 Jan-Feb;15(1):1-6
pubmed: 19197165
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):573-589
pubmed: 29280452
Radiat Oncol. 2013 Sep 04;8:206
pubmed: 24007322
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30
pubmed: 17544601
Oncotarget. 2019 Jul 16;10(44):4513-4515
pubmed: 31360300
J Clin Oncol. 2018 Jun 20;36(18):1780-1784
pubmed: 29718792
Am J Clin Oncol. 2018 Jun;41(6):558-567
pubmed: 27635624